Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BTK |
| Variant | Y361H |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | BTK Y361H lies within the SH2 domain of the Btk protein (UniProt.org). Y361H retains binding to Plcg2 and Cdc37, and demonstrates Plcg2 phosphorylation and Btk autophosphorylation levels similar to wild-type Btk, but results in decreased protein stability and expression, and elevated phosphorylation of Akt in anti-immunoglobulin treated cells in culture (PMID: 33419778), and therefore, its effect on Btk protein function is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
BTK mutant BTK Y361H |
| Transcript | NM_000061.3 |
| gDNA | chrX:g.101358331A>G |
| cDNA | c.1081T>C |
| Protein | p.Y361H |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000061.3 | chrX:g.101358331A>G | c.1081T>C | p.Y361H | RefSeq | GRCh38/hg38 |
| NM_000061.2 | chrX:g.101358331A>G | c.1081T>C | p.Y361H | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK Y361H | lymphoma | sensitive | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a lymphoma cell line expressing BTK Y361H was sensitive to Imbruvica (ibrutinib) treatment in culture, demonstrating decreased cell viability (PMID: 33419778). | 33419778 |